LIGAND PHARMACEUTICALS INC
LGNDZN/A
NASDAQBiotechnology🇺🇸North America
Drugs in Pipeline
3
Phase 3 Programs
1
Upcoming Catalysts
1
Next Catalyst
Nov 23, 2026
36wMarket Overview
Stock performance and key metrics
LGNDZ News
Catalyst Timeline
1 upcoming, 0 past
Drug Pipeline
lasofoxifene
Osteoporosis
Aplindore
Restless Legs Syndrome
Bexarotene
Sarcoma, Kaposi
| Drug Name | Phase | Indication | Designations | Patent |
|---|---|---|---|---|
lasofoxifene | Phase 3 | Osteoporosis | - | - |
Aplindore | Phase 2 | Restless Legs Syndrome | - | - |
Bexarotene | Phase 2 | Sarcoma, Kaposi | - | - |
Regulatory Approvals
Data is aggregated from public sources (FDA, SEC, ClinicalTrials.gov). While we strive for accuracy, information may be incomplete, delayed, or contain errors. Terms apply